Physician profile
German Castro
NPI 1134186794
$16,843.46
in general payments reported to CMS, 2019-2025
43 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,725 · 2020: $1,171 · 2021: $2,631 · 2022: $2,531 · 2023: $1,749 · 2024: $1,887 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,785.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,147.11 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $2,520.53 | 2019-2023 | Xarelto |
| Amgen INC. | $1,903.92 | 2019-2024 | Evenity |
| Novo Nordisk INC | $999.53 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $831.97 | 2019-2024 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.36 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $380.77 | 2022-2023 | |
| Astellas Pharma US INC | $317.48 | 2019 | |
| Sanofi-Aventis U.S. LLC | $280.54 | 2019 | |
| Glaxosmithkline, LLC. | $253.84 | 2019-2023 | Arexvy, Shingrix |
| Corcept Therapeutics | $233.94 | 2025 | Korlym |
| Lilly USA, LLC | $232.76 | 2019-2024 | Jardiance |
| Daiichi Sankyo INC. | $228.25 | 2020-2025 | Enhertu |
| Paratek Pharmaceuticals, INC. | $214.40 | 2023 | Nuzyra |
| Esperion Therapeutics, INC. | $187.31 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw German Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.